SCHEMBL863754

SCHEMBL863754

COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4F)c(Cl)c3)c2cc1C(N)=O

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 9/20 0.81
FGFR4 P22455 8/20 0.81
PDGFRA P16234 5/20 0.81
RET P07949 5/20 0.81
PDGFRB P09619 4/20 0.81
FGFR1 P11362 4/20 0.81
AURKB Q96GD4 4/20 0.81
KIT P10721 3/20 0.81
FLT1 P17948 3/20 0.81
FLT4 P35916 3/20 0.81
RIPK2 O43353 2/20 0.81
STK10 O94804 2/20 0.81
ABL1 P00519 2/20 0.81
BCR P11274 2/20 0.81
SLC6A3 Q01959 2/20 0.81
DDR1 Q08345 2/20 0.81
MAP4K2 Q12851 2/20 0.81
PTK6 Q13882 2/20 0.81
DDR2 Q16832 2/20 0.81
RIPK3 Q9Y572 2/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL863755 1.00 KDR (0.81) KDRFGFR4PDGFRARETPDGFRB
Lenvatinib SCHEMBL864638 0.89 FGFR4 (1.00) KDRFGFR4PDGFRARETPDGFRB
Lenvatinib SCHEMBL29372021 0.89 FGFR4 (1.00) KDRFGFR4PDGFRARETPDGFRB
Lenvatinib SCHEMBL29349806 0.89 FGFR4 (1.00) KDRFGFR4PDGFRARETPDGFRB
SCHEMBL12673521 0.89 KDR (0.64) KDRFGFR4PDGFRARETPDGFRB
SCHEMBL23366513 0.89 KDR (0.83) KDRFGFR4PDGFRARETPDGFRB
SCHEMBL1889145 0.89 FGFR4 (0.78) KDRFGFR4PDGFRARETPDGFRB
SCHEMBL1889146 0.89 FGFR4 (0.78) KDRFGFR4PDGFRARETPDGFRB
Lenvatinib SCHEMBL1389214 0.89 FGFR4 (0.98) KDRFGFR4PDGFRARETPDGFRB
SCHEMBL863668 0.86 KDR (0.79) KDRFGFR4PDGFRARETPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110293615-A1 Use of Combination of Anti-Angiogenic Substance and c-kit Kinase Inhibitor EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-12-01 US claimed
EP-2281901-A2 Anti-tumour pharmaceutical composition with angiogenesis inhibitors Eisai R&D Management Co., Ltd. (JP) 2011-02-09 EP claimed
EP-2248804-A1 COMBINED USE OF ANGIOGENESIS INHIBITOR AND TAXANE Eisai R&D Management Co., Ltd. (JP) 2010-11-10 EP claimed
US-20100239688-A1 COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND ANTI-TUMOR PLATINUM COMPLEX EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-09-23 US claimed
EP-2218712-A1 COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND ANTI-TUMOR PLATINUM COMPLEX Eisai R&D Management Co., Ltd. (JP) 2010-08-18 EP claimed
US-20100105031-A1 METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR ESAI R & D MANAGEMENT CO., LTD. (JP) 2010-04-29 US claimed
US-20100092490-A1 METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-04-15 US claimed
EP-2116246-A1 COMPOSITION FOR TREATMENT OF PANCREATIC CANCER Eisai R&D Management Co., Ltd. (JP) 2009-11-11 EP claimed
US-20090264464-A1 ANTITUMOR AGENT FOR UNDIFFERENTIATED GASTRIC CANCER EISAI R & D MANAGEMENT CO., LTD. (JP) 2009-10-22 US claimed
US-20090247576-A1 ANTI-TUMOR AGENT FOR MULTIPLE MYELOMA EISAI R & D MANAGEMENT CO., LTD. (JP) 2009-10-01 US claimed
US-20090209580-A1 ANTITUMOR AGENT FOR THYROID CANCER EISAI R & D MANAGEMENT CO., LTD. (JP) 2009-08-20 US claimed
US-20090203693-A1 THERAPEUTIC AGENT FOR LIVER FIBROSIS EISAI R & D MANAGEMENT CO., LTD. (JP) 2009-08-13 US claimed
EP-2065372-A1 ANTITUMOR AGENT FOR UNDIFFERENTIATED GASTRIC CANCER Eisai R&D Management Co., Ltd. (JP) 2009-06-03 EP claimed
EP-2036557-A1 ANTITUMOR AGENT FOR THYROID CANCER Eisai R&D Management Co., Ltd. (JP) 2009-03-18 EP claimed
US-20090053236-A1 USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR EISAI R & D MANAGEMENT CO., LTD. (JP) 2009-02-26 US claimed
EP-1949902-A1 USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR Eisai R&D Management Co., Ltd. (JP) 2008-07-30 EP claimed
EP-1925676-A1 METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR Eisai R&D Management Co., Ltd. (JP) 2008-05-28 EP claimed
EP-1925941-A1 METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR Eisai R&D Management Co., Ltd. (JP) 2008-05-28 EP claimed
EP-1797877-A1 JOINT USE OF SULFONAMIDE BASED COMPOUND WITH ANGIOGENESIS INHIBITOR Eisai Co., Ltd. (JP) 2007-06-20 EP claimed
US-20060135486-A1 Use of sulfonamide-including compounds in combination with angiogenesis inhibitors EISAI CO., LTD. (JP) 2006-06-22 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239688-A1 COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND ANTI-TUMOR PLATINUM COMPLEX PGF, VEGFA, FLT4 KDR 16/4885FGFR4 389/4885PDGFRA 382/4885
US-20090247576-A1 ANTI-TUMOR AGENT FOR MULTIPLE MYELOMA FGFR3, MCTS1, TP53 KDR 2806/4885FGFR4 5/4885PDGFRA 3371/4885
US-20060135486-A1 Use of sulfonamide-including compounds in combination with angiogenesis inhibitors FLT4, KDR, FLT1 KDR 2/4885FGFR4 49/4885PDGFRA 13/4885
US-20090209580-A1 ANTITUMOR AGENT FOR THYROID CANCER MEN1, VHL, NTSR2 KDR 2455/4885FGFR4 1779/4885PDGFRA 2701/4885
US-20100092490-A1 METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR VEGFA, FLT4, MKI67 KDR 6/4885FGFR4 70/4885PDGFRA 83/4885
US-20110293615-A1 Use of Combination of Anti-Angiogenic Substance and c-kit Kinase Inhibitor KIT, FLT4, KDR KDR 3/4885FGFR4 476/4885PDGFRA 10/4885
US-20090203693-A1 THERAPEUTIC AGENT FOR LIVER FIBROSIS HDGF, MMP1, FABP1 KDR 3906/4885FGFR4 1189/4885PDGFRA 150/4885
US-20090264464-A1 ANTITUMOR AGENT FOR UNDIFFERENTIATED GASTRIC CANCER FGFR2, FGFR3, FGF2 KDR 340/4885FGFR4 6/4885PDGFRA 166/4885
US-20090053236-A1 USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR KIT, FLT4, KDR KDR 3/4885FGFR4 476/4885PDGFRA 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.